Skip to content
Search

Latest Stories

Valproate National Patient Safety Alert – GPhC tells what pharmacists need to do

Valproate National Patient Safety Alert – GPhC tells what pharmacists need to do
Valproate National Patient Safety Alert

Pharmacy teams should be prepared to discuss the current warnings and upcoming measures with their patients

The General Pharmaceutical Council (GPhC) on Thursday sent an email to all pharmacy professionals to update them about a Valproate National Patient Safety Alert issued by the Medicines and Healthcare products Regulatory Agency (MHRA).


From January 2024, the MHRA is introducing the first phase of new regulatory measures to reduce the known harms of valproate, a drug used to treat epilepsy and bipolar disorder.

The health regulator has cautioned that the drug may cause serious harm to the baby, if taken during pregnancy, and lead to impaired fertility in males.

Integrated Care Boards in England and Health Boards in Scotland and Wales have been instructed to designate a new or existing group to prepare for and co-ordinate the implementation of the measures for oversight of prescribing valproate to new patients and existing female patients.

Meanwhile, the GPhC has informed pharmacy teams that they should be prepared to discuss the current warnings and upcoming measures with their patients.

However, pharmacist should continue to dispense valproate, as well as remind patients who are taking the drug that they must not stop taking their treatment without advice from their specialist.

Additionally, the regular have gathered existing resources and information about valproate and made it available on its website to help pharmacists to stay up-to-date.

The GPhC has also appealed to pharmacy teams to spread this important information in the sector.

New regulatory measures for valproate prescribing

The MHRA says:

From January 2024, valproate must not be started in new patients (male or female) younger than 55 years, unless two specialists independently consider and document that there is no other effective or tolerated treatment, or unless there are compelling reasons that the reproductive risks do not apply. For the majority of patients, other effective treatment options are available.

Women of childbearing potential and and girls who are currently taking valproate should be reviewed at their next annual specialist review, using a revised valproate Annual Risk Acknowledgement Form, which will include the need for a second opinion’s signature if the patient is to continue with valproate.

The regulatory measures will be introduced in a phased manner to ensure ongoing patient care is not disrupted, as recommended by the independent group Commission on Human Medicines

 

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less